Lobbyist Insight

Colorado · 2021-2022

HB22-1344

FDA-approved Prescription 3,4-Methylenedioxymethamphetamine Drug Use

Read HB22-1344 at the Colorado legislature →

10 registered positions on this bill · 10 state a side.

Lobbyist or firmFor clientPositionSession
Colorado Legislative StrategiesColorado BioScience AssociationMonitoring2021-2022
Crews, Michael AnthonyColorado BioScience AssociationMonitoring2021-2022
BRANDEBERRY MCKENNA PUBLIC AFFAIRSColorado Hospital AssociationMonitoring2021-2022
Ewing, JoshuaColorado Hospital AssociationMonitoring2021-2022
MULREADY, KATHERINEColorado Hospital AssociationMonitoring2021-2022
WHITE, JOHNDenver Department of Public SafetyMonitoring2021-2022
Colorado Legislative StrategiesEmergent BiosolutionsMonitoring2021-2022
Headwaters StrategiesMAPS Public Benefit CorporationSupporting2021-2022
Deborah A. Wagner, LLCMt Carmel Veterans Service CenterMonitoring2021-2022
Keller, Maryanne "Moe"mental health coloradoMonitoring2021-2022

Positions are as filed. A lobbyist may file more than once as a position changes.